Online inquiry

IVTScrip™ mRNA-Anti-CD3E&MS4A1, REGN-1979(Cap 0, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ13875MR)

This product GTTS-WQ13875MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets CD3E&MS4A1 gene. The antibody can be applied in Chronic lymphocytic leukemia (CLL), Non-Hodgkin's lymphoma (NHL) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_000733.4; NM_021950.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 916; 931
UniProt ID P07766; P11836
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD3E&MS4A1, REGN-1979(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ13875MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ7994MR IVTScrip™ mRNA-Anti-GHR, GX-H9(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA GX-H9
GTTS-WQ10966MR IVTScrip™ mRNA-Anti-IL17A&IL17F, MCAF-5352A(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MCAF-5352A
GTTS-WQ13367MR IVTScrip™ mRNA-Anti-LRRC15, PR-1498487(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA PR-1498487
GTTS-WQ10205MR IVTScrip™ mRNA-Anti-ITGA4&ITGB7, LDP-02(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA LDP-02
GTTS-WQ10733MR IVTScrip™ mRNA-Anti-FCGRT, M-281(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA M-281
GTTS-WQ14725MR IVTScrip™ mRNA-Anti-CD19, SGN-19A(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA SGN-19A
GTTS-WQ1553MR IVTScrip™ mRNA-Anti-BMP10&GDF2, ACE-041(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA ACE-041
GTTS-WQ3437MR IVTScrip™ mRNA-Anti-HGF, AV-299(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA AV-299
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW